Structured Education Based on New Glucose Management Devices in Patients With Type 1 Diabetes Mellitus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-26

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Continuous glucose monitoring (CGM) and insulin pump, a new medical device, have been proved and highly recommended in the treatment of type 1 diabetes patients worldwide, and related technology development and market are growing rapidly.

In order to maximize the medical and socioeconomic effects of the latest blood glucose devices including CGM and insulin pump, structured education is necessary. In this study, we will develop patient-oriented structured education for patients with type 1 diabetes mellitus when applying CGM, and we will assess the efficacy of this education protocol for patients with type 1 diabetes using CGM.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Individualized Automatic Coaching Message for Glycemic Management and Depressive Symptom

NCT06684678

Diabetes Mellitus, Type 1 Continuous Glucose Measurement

NOT_YET_RECRUITING NA

Individualized Automatic Target Coaching Message for Glycemic Management and Depressive Symptom

NCT06525454

Diabetes Mellitus, Type 1

COMPLETED NA

Web-Based Intervention Designed to Educate and Improve Adherence Through Learning to Use Continuous Glucose Monitoring

NCT03367351

Type 1 Diabetes Mellitus Continuous Glucose Monitor

COMPLETED NA

Research on Optimizing the Use of Technology With Education

NCT05564481

Type 1 Diabetes Continuous Glucose Monitoring Behavioral Intervention +1 more

ACTIVE_NOT_RECRUITING NA

The Effect of Online Based Mentoring Program on the Blood Glucose and Satisfaction Score in Type 1 Diabetes Patients

NCT01157611

Type 1 Diabetes

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In 50 patients with type 1 diabetes with over 7% of glycated hemoglobin, whose blood glucose level is not well controlled, and who are undergoing multiple daily insulin injection therapy or insulin pump therapy, continuous glucose monitoring (CGM) is applied to obtain basal continuous glucose levels for 1 week (window period of 2 week).

These 50 patients are 1:1 randomly assigned to 2 groups including control group and intervention group. Control group (n=25) applied CGM without structured education and after 3 months of applying CGM, continuous glucose data for 2 consecutive weeks and HbA1c level, and other glycometabolic parameters are collected. As a sequential extension clinical trial, those 25 patients in control group are provided structured education, followed by applying CGM for 3 months. Continuous glucose levels for 2 consecutive weeks and HbA1c level, and other glycometabolic parameters are collected.

In Intervention group (n=25), structured education program is provided for each patient from the time of enrollment, followed by applying CGM for 3 months. Continuous glucose levels for 2 consecutive weeks and HbA1c level and other blood tests are performed after the 3 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

CGM apply followed by structured education of CGM

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

Without structured education when applying CGM for 3months, and as a sequential extension clinical trial, after 3 months, structured education is provided, followed by CGM apply

Group Type PLACEBO_COMPARATOR

Structured Education for new glucose management devices

Intervention Type BEHAVIORAL

Individualized professional education based on new glucose management devices in patients with type 1 diabetes mellitus

Intervention

provide structured education when applying CGM for 3 months

Group Type ACTIVE_COMPARATOR

Structured Education for new glucose management devices

Intervention Type BEHAVIORAL

Individualized professional education based on new glucose management devices in patients with type 1 diabetes mellitus

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Structured Education for new glucose management devices

Individualized professional education based on new glucose management devices in patients with type 1 diabetes mellitus

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Over 18 years old - under 70 years old patients with Type 1 diabetes
* Those who plan to use CGM G5
* Patients who consented to use CGM G5 in conjunction with Clarity
* Those who are using multiple insulin injections or insulin pumps for at least 3 months
* Those whose fasting c-peptide \<0.6 ng / dL, or stimulated c-peptide \<1.8 ng / dL
* Those with a glycated hemoglobin of 7.0% or more within the last 3 months
* Those who have never used a CGM for more than a month
* For women of childbearing age, those who agree to use appropriate contraception during the trial
* Those who voluntarily signed the agreement after the explanation of the clinical trial

Exclusion Criteria

* Those with a history of severe hypoglycemia and acute ketoacidosis within the last 3 months
* Patients with chronic renal function greater than or equal to stage 4 (estimated glomerular filtration rate \[assessed by MDRD (modification of diet in renal disease\] \<30 )
* Patients with acute myocardial infarction, unstable angina, coronary artery disease or stroke within the last 3 months
* Patients with adrenal insufficiency, pituitary dysfunction, medically uncontrolled hyperthyroidism or hypothyroidism
* Those taking medications that can affect the glucose metabolism (eg, corticosteroids, immunostimulants, etc.)
* Pregnant and lactating women
* A person who is deemed unsuitable for participation in clinical trials by examiners

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No